Harmaline structure
|
Common Name | Harmaline | ||
---|---|---|---|---|
CAS Number | 304-21-2 | Molecular Weight | 214.263 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 426.4±45.0 °C at 760 mmHg | |
Molecular Formula | C13H14N2O | Melting Point | 232-234 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 211.7±28.7 °C |
Use of HarmalineHarmaline is a potent and reversible monoamine oxidase inhibitor in vivo. Harmaline is a central nervous system stimulant and can be used to induce tremor in rodents. |
Name | harmaline |
---|---|
Synonym | More Synonyms |
Description | Harmaline is a potent and reversible monoamine oxidase inhibitor in vivo. Harmaline is a central nervous system stimulant and can be used to induce tremor in rodents. |
---|---|
Related Catalog | |
Target |
Target: Monoamine oxidase[1] |
In Vitro | Harmaline inhibits monoamine oxidases, thus increasing the levels of monoamine neurotransmitters (e.g., at 7-70 μM/kg in rats)[1]. Harmaline-induced tremor in rodents is a model of essential tremor. The tremor activity is dependent on harmaline dose. The first-line clinical essential tremor treatments propranolol, primidone and gabapentin and γ-hydroxybutyrate (GHB) significantly attenuate harmaline-induced tremor. The anticonvulsants valproate and carbamazepine and the mood stabilizer lithium suppress harmaline-induced tremor. The γ-amino-butyric acid (GABA) receptor subtype A receptor agonist muscimol attenuate harmaline-induced tremor. Harmaline (30 mg/kg) induces tremor in mice through the N-methyl-D-aspartate (NMDA) receptor, both competitive and non-competitive NMDA receptor antagonists, and AMPA receptor blockade, decreased harmaline-induced tremor[2]. |
Animal Admin | Rats[1] Wistar albino rats of 160 to 190 g, fasted for 16 hr, receive various doses of Harmaline (0-70 μM/kg) either alone or 1 hr prior to subcutaneous administration of 75 mg/kg 5-hydroxytryptophan, 10 mg/kg Ro 4-1284 or 100 mg/kg iproniazid. The animals are decapitated and the 5-hydroxytryptamine of the brain (in the experiments with 5-hydroxytryptophan also of the heart) is measured spectrophotofluorometrically[1]. Mice[2] Group-housed mice are brought to the experimental room for at least 1 h to acclimate prior to testing. Following a 20 min pretreatment with vehicle or test compounds (60 min for primidone), drug-naive mice are injected with harmaline (30 mg/kg) and placed inside the Tremor Monitor chamber for a 10 min habituation period. Following the habituation period, tremor activity of the mice is measured for 8 min[2]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 426.4±45.0 °C at 760 mmHg |
Melting Point | 232-234 °C(lit.) |
Molecular Formula | C13H14N2O |
Molecular Weight | 214.263 |
Flash Point | 211.7±28.7 °C |
Exact Mass | 214.110611 |
PSA | 37.38000 |
LogP | 0.66 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.647 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xn |
Risk Phrases | R25 |
Safety Phrases | S22-S24/25 |
RIDADR | 1544 |
WGK Germany | 3 |
RTECS | UU9800000 |
Packaging Group | III |
Hazard Class | 6.1(b) |
HS Code | 2933990090 |
~% Harmaline CAS#:304-21-2 |
Literature: Chemische Berichte, , vol. 63, p. 120,123 |
~% Harmaline CAS#:304-21-2 |
Literature: Canadian Journal of Chemistry, , vol. 37, p. 1851,1856 |
~% Harmaline CAS#:304-21-2 |
Literature: Canadian Journal of Chemistry, , vol. 37, p. 1851,1856 |
~% Harmaline CAS#:304-21-2 |
Literature: Chem. Zentralbl., , vol. 72, # I p. 958 Justus Liebigs Annalen der Chemie, , vol. 64, p. 365 Chemische Berichte, , vol. 18, p. 402 Chemische Berichte, , vol. 30, p. 2482 |
~% Harmaline CAS#:304-21-2 |
Literature: Chemische Berichte, , vol. 63, p. 120,123 |
Precursor 5 | |
---|---|
DownStream 8 | |
HS Code | 2933990090 |
---|---|
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
High-throughput screening for new psychoactive substances (NPS) in whole blood by DLLME extraction and UHPLC-MS/MS analysis.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 1000 , 57-68, (2015) The increasing number of new psychoactive substances (NPS) present in the illicit market render their identification in biological fluids/tissues of great concern for clinical and forensic toxicology.... |
|
Fast determination of harmala alkaloids in edible algae by capillary electrophoresis mass spectrometry.
Anal. Bioanal. Chem 407(13) , 3637-45, (2015) The use of algae as a foodstuff is rapidly expanding worldwide from the East Asian countries, where they are also used for medical care. Harmala alkaloids (HAlk) are a family of bioactive compounds fo... |
|
Rapid and sensitive detection of the inhibitive activities of acetyl- and butyryl-cholinesterases inhibitors by UPLC-ESI-MS/MS.
J. Pharm. Biomed. Anal. 94 , 215-20, (2014) Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are legitimate therapeutic targets for Alzheimer's disease. The classical approach for screening potential AChE/BChE inhibitors was develop... |
3,4-Dihydroharmine |
Armalin |
3,4-Dihydro-7-methoxy-1-methyl-9H-pyrido[3,4-b]indole |
2H-Pyrido[3,4-b]indole, 3,4-dihydro-7-methoxy-1-methyl- |
7-Methoxy-1-methyl-3,4-dihydro-2H-β-carboline |
Harmine,dihydro |
7-methoxy-1-methyl-3,4-dihydro-2H-pyrido[3,4-b]indole |
Harmalol methyl ether |
EINECS 206-152-6 |
MFCD00004955 |
3,4-Dihydro-7-methoxy-1-methyl-β-carboline |
Dihydroharmine |
Harmidine |
O-Methylharmalol |